Abbott

ABBOTT PARK, Ill., May 22, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Deutsche Bank 38(th) Annual Health Care Conference on Wednesday, May 29, 2013. Thomas C. Freyman, executive vice president, finance and chief financial officer, and Scott White, senior vice president, international nutrition, will ... read more

ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition(TM) 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due ... read more

ABBOTT PARK, Ill., May 9, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes. As of ... read more

ABBOTT PARK, Ill., May 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013. Thomas C. Freyman, executive vice president, finance and chief financial officer, and Brian Blaser, executive vice president, diagnostics products, will present at 7:30 ... read more

ABBOTT PARK, Ill., April 18, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the TECNIS(®) Toric 1-Piece intraocular lens (IOL) has received U.S. Food and Drug Administration (FDA) approval and is launching in the United States for the treatment of cataract patients with pre-existing corneal astigmatism. Corneal ... read more

ABBOTT PARK, Ill., April 17, 2013 /PRNewswire/ -- Abbott today announced financial results for the first quarter ended March 31, 2013. -- First-quarter adjusted diluted EPS was $0.42, at the high end of previous guidance; reported diluted EPS from ... read more

ABBOTT PARK, Ill., April 16, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the global launch of the ACCELERATOR(®) a3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling increased volume. Advances in technology and automation within the lab ... read more

ABBOTT PARK, Ill., April 15, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it is initiating a voluntary recall of FreeStyle InsuLinx(®) Blood Glucose Meters in the United States. The company has determined that at extremely high blood glucose levels of 1024 mg/dL and above, the FreeStyle InsuLinx Meter will display ... read more

ABBOTT PARK, Ill., April 10, 2013 /PRNewswire/ -- Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partnership with BG Medicine, ... read more

ABBOTT PARK, Ill., April 1, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2013 financial results on Wednesday, April 17, 2013, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ... read more

ABBOTT PARK, Ill., March 28, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the ARCHITECT AFP test, which may help doctors detect serious birth defects and the progression of testicular cancer, received U.S. Food and Drug Administration (FDA) approval. Biomarkers, such as alpha-fetoprotein (AFP), are substances in the body ... read more

ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip(®) ... read more

SAN FRANCISCO, March 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive long-term results for the company's innovative Absorb(TM) Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented at the 62nd Annual Scientific Session ... read more

SAN FRANCISCO, March 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip(®) System for the treatment of mitral regurgitation (MR). Findings were presented today at the 62nd Annual Scientific ... read more

ABBOTT PARK, Ill., March 7, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Barclays Capital 2013 Global Healthcare Conference on Thursday, March 14, 2013. Thomas C. Freyman, executive vice president, finance and chief financial officer, will present at 7:30 a.m. Central time. A live audio ... read more

ABBOTT PARK, Ill., March 5, 2013 /PRNewswire/ -- Abbott's (NYSE: ABT) ZonePerfect brand today introduces a new line of nutrition bars for active kids, Kidz ZonePerfect. Built directly with the help of parents and their children, Kidz ZonePerfect features five grams of protein, 23 vitamins and minerals and three grams ... read more

ABBOTT PARK, Ill., Feb. 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to ... read more

ABBOTT PARK, Ill., Feb. 15, 2013 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 14 cents per share. This marks the 357(th) consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable ... read more

ABBOTT PARK, Ill., Feb. 12, 2013 /PRNewswire/ -- (NYSE: ABT) - A national survey of fitness enthusiasts who exercise three or more times a week show a strong dedication to reaching fitness goals; however the vast majority -- 82 percent-- admitted to falling short when it comes to post-workout ... read more

ABBOTT PARK, Ill., Jan. 23, 2013 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2012. -- Fourth-quarter diluted earnings per share, excluding specified items, were $1.51. Diluted earnings per share under Generally Accepted ... read more